<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Durect Corp.</title>
	<atom:link href="http://www.stockbloghub.com/tag/durect-corp/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(KG) King Pharmaceuticals Launches Embeda for Around-The-Clock Pain Relief</title>
		<link>http://www.stockbloghub.com/2009/09/24/kg-king-pharmaceuticals-launches-embeda-for-around-the-clock-pain-relief/16013</link>
		<comments>http://www.stockbloghub.com/2009/09/24/kg-king-pharmaceuticals-launches-embeda-for-around-the-clock-pain-relief/16013#comments</comments>
		<pubDate>Thu, 24 Sep 2009 19:39:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corp.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=16013</guid>
		<description><![CDATA[Earlier this week, King Pharmaceuticals, Inc. (KG) announced the launch of Embeda, which recently received U.S. Food and Drug Administration (FDA) approval for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Embeda, which is the first FDA-approved long-acting opioid designed to reduce drug liking and euphoria when tampered with by crushing or chewing, will be available in six dosage strengths. As per the requirement of the FDA, the company has also implemented a Risk Evaluation and Mitigation Strategy (REMS) under which patients and providers will be informed about the potential for abuse, misuse, overdose, and addiction of Embeda and about the safe use of the opioid. The approval and launch of Embeda is a significant milestone for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/24/kg-king-pharmaceuticals-launches-embeda-for-around-the-clock-pain-relief/16013/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

